Beleaguered Biogen has been handed some encouraging news from the FDA, after the regulator agreed to complete its review of amyotrophic lateral sclerosis (ALS) therapy tofersen within six months ...

He has also held executive roles at Alchemab Therapeutics and TScan Therapeutics and spent over a decade at Eli Lilly and Company in corporate business development and global partnerships. Dr.

Explore the clinical trends expected for 2025 - including ADCs, Radiopharmaceuticals, CGTs, AAV, and rare diseases. Stay ahead of the curve with these industry insights.

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and more than $650 million in milestones.

Telehealth partners for Eli Lilly (LLY) continue to sell compounded GLP-1 weight-loss drugs despite an agreement with the pharma giant to end copycat sales after the FDA ended a years-long ...

Nova Scotia's Royal Canadian Mounted Police (RCMP) announced on Wednesday that investigators have conducted polygraph interviews as part of the effort to determine what happened to Lilly and Jack ...

INDIANAPOLIS, June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per ...

Eli Lilly (NYSE:LLY) lands an $870 million pact with Camurus (CAMX) to build long-acting obesity treatments, tapping FluidCrystalslow-release tech to stretch dosing from days to weeks. Lilly's ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothold in ...